key: cord-1027237-3sobmfqz
authors: Karthik, Kumaragurubaran; Aravindh Babu, Ramasamy Parthiban; Dhama, Kuldeep; Chitra, Murugesan Ananda; Kalaiselvi, Govindan; Alagesan Senthilkumar, Tuticorin Maragatham; Raj, Gopal Dhinakar
title: Biosafety Concerns During the Collection, Transportation, and Processing of COVID-19 Samples for Diagnosis
date: 2020-09-12
journal: Arch Med Res
DOI: 10.1016/j.arcmed.2020.08.007
sha: cb05db534ef120090a9054ba27c9069c0710f6d3
doc_id: 1027237
cord_uid: 3sobmfqz

The coronavirus disease 2019 (COVID-19) pandemic, which started in China, has created a panic among the general public and health care/laboratory workers. Thus far, there is no medication or vaccine to prevent and control the spread of COVID-19. As the virus is airborne and transmitted through droplets, there has been significant demand for face masks and other personal protective equipment to prevent the spread of infection. Health care and laboratory workers who come in close contact with infected people or material are at a high risk of infection. Therefore, robust biosafety measures are required at hospitals and laboratories to prevent the spread of COVID-19. Various diagnostic platforms including of serological, molecular and other advanced tools and techniques have been designed and developed for rapid detection of SARS-CoV-2 and each has its own merits and demerits. Molecular assays such as real-time reverse transcriptase polymerase chain reaction (rRT-PCR) has been used worldwide for diagnosis of COVID-19. Samples such as nasal swabs or oropharyngeal swabs are used for rRT-PCR. Laboratory acquired infection has been a significant problem worldwide, which has gained importance during the current pandemic as the samples for rRT-PCR may contain intact virus with serious threat. COVID-19 can spread to workers during the sampling, transportation, processing, and disposal of tested samples. Here, we present an overview on advances in diagnosis of COVID-19 and details the issues associated with biosafety procedures and potential safety precautions to be followed during collection, transportation, and processing of COVID-19 samples for laboratory diagnosis so as to avoid virus infection.

with COVID-19 (7) (8) (9) . Italy, reports higher morbidity of 10.7% COVID-19 cases among health care workers (10) . The mortality rate associated with COVID-19 among health care workers was 0.35% (6 out of 1700 cases), while that associated with severe acute respiratory syndrome (SARS) in 2002 was 1.45% (5 out of 343 cases) (9, 11) . These data show the importance of having robust biosafety procedures not only for patient care givers like doctors and nurses but also for persons processing the sample for the diagnosis of COVID-19. Health care and laboratory workers are at a high risk of infection because of being in close contact with infected patients and material and a lack of personal protective equipment (PPE) (6) . For health care and laboratory workers involved in COVID-19 testing, PPE is the only defense available to avoid being infected (12) .

The safety of laboratory workers involved in the diagnosis of COVID-19 is of increased concern as there is no clear picture of infections in laboratory settings. Laboratory-associated infection may occur due to a lack of PPE, improper microbiological techniques, lack of training, and inadequate decontamination protocols (13) . A graduate student in Singapore in 2003 and a researcher in Taiwan in 2004 had been infected by SARS in the laboratory setting (13) . Thus, there is similar chance of COVID-19 transmission to laboratory workers. Hence, it is important to consider biosafety issues concerning laboratory procedures during the current COVID-19

pandemic. Here, we aimed to address the safety issues faced by laboratory workers involved in the processing COVID-19 samples and detail potential safety precautions that can be implemented to avoid virus infection and prevent the spread of COVID-19. A brief overview on the recent advances in diagnosis of SARS-CoV-2/COVID-19 has also been presented. Biosafety issues during the collection, transportation, and processing of COVID-19 samples for laboratory diagnosis are addressed in detail.

J o u r n a l P r e -p r o o f Real time PCR is the globally used in vitro diagnostic assay for the confirmation of SARS-CoV-2 in clinical samples. Availability of whole genome of SARS-CoV-2 in the public domain led to the development of several RT-PCR methods using different target genes (14) . Genes like envelope (E), RNA-dependent RNA polymerase (RdRp), spike (S), nuceloprotein (N), open reading frame (ORF) 1a, ORF 1b and non structural protein (NSP) 2 are employed as targets for rRT-PCR detection of the virus (15) (16) (17) . Variations and up gradation of the existing assays are increasing day by day to detect SARS-CoV-2 with improved sensitivity of the assays. RdRp/helicase (Hel) gene targeted rRT-PCR was reported to be more sensitive and has limit of detection of 1.80 TCID 50 /mL using genomic RNA (18, 19) . Triplex rRT-PCR targeting N and E gene of SARS-CoV-2 along with an internal control has been developed which had reduced sensitivity as compared with uniplex rRT-PCR (20) . Occasional issues of false negative results of rRT-PCR have been reported from various countries (21) . As per the report of Foundation for Innovative New Diagnostics (FIND), a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation, 313 different molecular assay platforms are available for diagnosis of COVID-19.

The rRT-PCR assay requires sophisticated instruments and consumes time. Hence isothermal amplification assays like loop mediated isothermal amplification assays (LAMP) can be employed as a bed-side test (22, 23) . This assay can minimize the time required for declaring a result and it is a highly sensitive assay. Recently, LAMP assay targeting SARS-CoV-2 ORF1ab and S gene was developed with 100% specificity and sensitivity (24) . Similarly, N gene-based LAMP assay has also been developed with 100% sensitivity but its specificity with SARS and MERS were not tested (25) . Combination of Recombinase Polymerase Amplification (RPA) with LAMP assay in a single tube termed as Penn-RAMP has been developed which had higher sensitivity than LAMP assay (26) . Other platforms like CRISPR based point-of-care Specific High Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK) and DNA Endonuclease-Targeted CRISPR Trans Reporter J o u r n a l P r e -p r o o f (DETECTR) assays have also been developed for SARS-CoV-2 (27) . This assay employs both RPA with CRISPR-cas technology and report shows that CRISPR based assay requires lesser time than rRT-PCR but are less sensitive (28) . Metagenomic approaches are used for sequencing the SARS-CoV-2 samples thus enabling identification of the novel virus (29) . Hence, next generation sequencing (NGS) platforms can be used for efficient diagnosis of emerging or novel diseases. Due to the immediate need for diagnosing COVID-19 affected individuals, diagnostic potential of the few of the developed assays for detection of SARS-CoV-2 has not been properly elucidated, which needs necessary validation for confirmatory and practical use of the advanced diagnostics during COVID-19 pandemic (30) .

An array of antibody-based diagnostic assays has been developed to aid in point-of-care testing but they have the inherent problem of reduced sensitivity and specificity (31) . Assays like enzyme-linked immunosorbent assay (ELISA) and lateral flow assay (LFA) were developed for diagnosis of SARS-CoV-2. IgG and IgM assays based on recombinant S and N protein showed results comparable to rRT-PCR (32) . Reports show that IgA levels can be a marker for diagnosis of SARS-CoV-2 (33) . Other platforms like microfluidics and lab-on-chip assays are under development stages for point-of-care diagnosis of SARS-CoV-2.

The real-time COVID-19 tracking and mapping could be performed by using geographical information systems (GIS) (GIS softwareKosmo ® 3.1), web-based real-time dashboards, and advanced information technology platforms for designing useful apps, which would aid in checking the spread of the disease by adopting appropriate and timely prevention and control measures (34-37).

Social distancing among laboratory workers is vital as an asymptomatic colleague can infect J o u r n a l P r e -p r o o f others. In addition, robust hand hygiene should be followed. The health status of all laboratory workers should be regularly monitored for symptoms, and suspected laboratory workers should be quarantined. PPE, such as a lab coat or gown, face mask, face shield, gloves, goggles, and head cap, should be used during all laboratory procedures (10) . Aerosols or droplets are also generated while talking, and therefore, a mask should be worn even outside the laboratory (38). Under experimental conditions, SARS-CoV-2 has been found to be viable in aerosols for 3 hours. Thus, PPE should always be worn inside the laboratory to prevent infection (39). Although N95 face masks are recommended for all laboratory work that can generate aerosol droplets, there is a considerable shortage of N95 masks worldwide. If an N95 mask is not available, a surgical mask should be used. All workers should be trained on donning and doffing of PPE and decontamination procedures in case a spill occurs. Extra care should be taken while doffing PPE as there is a high chance of contamination during this procedure. Procedures such as centrifugation and vortexing during nucleic acid extraction can generate aerosols; hence, sealed rotor caps should be used while centrifugation and care should be taken to prevent contamination.

Lids should be tightly closed during centrifugation, the speed limit should not be exceeded, plastic centrifuge tubes should be used as glass tubes can break, and centrifuges should be used inside a biosafety cabinet (BSC) class II if possible (10) . Before processing COVID-19 samples, each laboratory should conduct a risk assessment, identify the potential hazards, prepare a standard operating procedure, and train laboratory workers to prevent the spread of COVID-19 (40).

rRT-PCR has been used extensively worldwide to confirm COVID-19 cases. The CDC recommends using upper respiratory samples such as oropharyngeal or nasopharyngeal samples for confirmation of SARS-CoV-2 using rRT-PCR (41,42). However, acquiring oropharyngeal or J o u r n a l P r e -p r o o f nasopharyngeal samples require close contact with suspected patients. SARS-CoV-2 is transmitted through respiratory droplets. Therefore, care should be taken during sample collection (43) . In the absence of respirators, eye protection goggles, gloves, and full-sleeved gown, N95 respirators, higher-level respirators, or face shield should be used (44) . Increased use of face masks by the general public has led to a shortage of masks for health care/laboratory workers (45, 46) . Health care workers collecting COVID-19 samples may be at risk of infection if the PPE, especially masks or respirators, are not available or not used properly. Other options for sample collection because of PPE shortage may be the self-collection of saliva samples (early-morning coughed-up sample) (47) . Saliva samples have been used for detecting several respiratory viruses, including SARS-CoV (48, 49) . Walk-in sample collection centers are used in India and South

Korea. These centers have a barrier between patients and health care workers, and swabs are taken with a gloved hand (50) . Although the effectiveness of these centers has not been validated, the transmission of COVID-19 to the health care worker may be reduced because of the barrier.

Movement or unwanted entry inside the sample collection area should be prevented since this can increase the risk of further spread.

The collected swabs should be transported in a viral transport medium to testing laboratories under cold conditions or at room temperature as per the recommendations (51) . If the specimen is When sending samples on a flight for international transport, UN3373 biological substance, category B regulations should be followed (52) . After packing and transporting the sample, the surface should be disinfected with agents that are known to be effective against SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) ( Table 1) . Cultures or isolates of SARS-CoV-2 should be transported as a UN2814 biological substance, category A and labeled as an infectious material affecting humans.

Once the sample is received by the testing laboratory, the outer container needs to be decontaminated and then sent to a biomedical waste management facility.

The laboratory should have three separate rooms for extraction of nucleic acid from sample, J o u r n a l P r e -p r o o f making a reaction mixture, and amplification. Samples should flow in a single direction to prevent contamination and false-positive amplification. Similarly, separate pipettes should be used for sample preparation, reaction mix preparation, and post-amplification procedures. Filtered tips may be used to prevent sample contamination (61) . A separate team of people may work on extraction and amplification procedures. The outer surface of the package should be disinfected with 70% ethanol or 0.1% sodium hypochloride before opening the package (62) . The specimens intended to undergo a nucleic acid amplification test should only be opened in a BSC class II A1 or A2 or higher-level biosafety cabinets such as BSC class III (63, 64) . Based on availability, samples can be handled in biosafety level 3 or 4 containment facilities. The required biosafety levels for various laboratory activities during the processing of SARS-CoV-2 samples, as recommended by the CDC, are presented in Table 2 . However, studies have shown that this not only inactivates the virus but also affects the nucleic acid amplification, producing false-negative results (67) . An automatic nucleic acid extractor can be used outside a BSC class II after the inactivation of the sample using a lysis buffer.

Once inactivated, the samples can undergo nucleic acid extraction. Even though theoretically, the samples have been inactivated after the addition of lysis buffer, care should still be taken, as there may be a chance of droplet spread during centrifugation and other procedures. Samples can be stored at -70ºC for extended storage or discarded after proper decontamination procedures. The entire working surface and equipment need to be decontaminated with disinfectants such as bleach, followed by 70% ethanol to remove the bleach residues (Table 1) . Regular crosscontamination checks of exposed laboratory surfaces should be performed to prevent erroneous results. The PPE used by laboratory workers and the laboratory medical waste generated should be autoclaved and appropriately packed before disposal to a biomedical waste management The biosafety measures to be implemented during COVID-19 testing are shown in Figure 2 .

As a general laboratory protocol, all used PPE and laboratory waste generated during the sample processing should be decontaminated before being discarded. Presently masks are used by all people around the world to prevent spread of COVID-19. There is limited awareness among the general public regarding the disposal of masks, and the majority of the masks used are discarded in the environment. It has been found that viruses can be detected at lower levels on the surface of J o u r n a l P r e -p r o o f masks, even 7 d after use (63) . Hence, face masks should be discarded carefully, and the general public should be informed of the same procedures. Improper disposal of face masks could potentially aid in the spread of COVID-19. Recent reports on the susceptibility of animals to SARS-CoV-2 are also concerning since stray dogs, cats, and other animals may come in contact with these masks, and if this occurs, it will be a significant issue (70) (Figure 3) .

Similarly, all laboratory waste generated during the processing of COVID-19 samples should be decontaminated before final disposal to a biomedical waste management facility. A list of disinfectants for SARS-CoV-2 and their manufacturers is available at the United States of America Environmental Protection Agency (https://www.epa.gov/pesticide-registration/list-ndisinfectants-use-against-sars-cov-2).

Since the SARS-CoV-2 is novel, there are several gray areas starting from its pathogenesis to treatment. People around the world are afraid about the fast spreading nature of the disease.

Presently testing and isolation is the only known method to prevent the spread of SARS-CoV-2.

Early diagnosis of COVID-19 is essential to cut the epidemic curve hence robust diagnostic assays are essential that can detect SARS-CoV-2 accurately and swiftly. Health care and laboratory workers are at risk and hence protective wears play a major role to prevent infection. J o u r n a l P r e -p r o o f 

Failure in initial stage containment of global COVID-19 epicenters

WHO. Coronavirus disease 2019 (COVID-19) Situation Report -135

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics

Novel coronavirus: how the things are in Wuhan

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Supporting the Health Care Workforce During the COVID-19 Global Epidemic

The spread of novel coronavirus has created an alarming situation worldwide

Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations

Epidemiologic clues to SARS origin in China

Challenges and solutions for addressing critical shortage of supply chain for personal and protective equipment (PPE) arising from Coronavirus disease (COVID19) pandemic -Case study from the Republic of Ireland

Improved Biosafety and Biosecurity Measures and/or Strategies to Tackle Laboratory-Acquired Infections and Related Risks

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Diagnosing COVID-19: The Disease and Tools for Detection

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Development of a Novel, Genome Subtraction-Derived

SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens

Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens

Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends

Triplex Real-Time RT-PCR for Severe Acute Respiratory Syndrome Coronavirus 2

False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence

Rapid colorimetric detection of COVID-19 coronavirus using a reverse tran-scriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic plat-form: iLACO

Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2

Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay

A Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2

Point-of-Care RNA-Based Diagnostic Device for COVID-19

A Protocol for Detection of COVID-19 Using CRISPR Diagnostics

CRISPR-Cas12-based detection of SARS-CoV-2

Era of molecular diagnosis for pathogen identification of unexplained pneumonia, lessons to be learned

Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2: A Narrative Review

Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis

Detection of serum IgM and IgG for COVID-19 diagnosis

COVID-19 diagnosis and study of serum SARS-CoV-2 specific

IgM and IgG by a quantitative and sensitive immunoassay

Mapping the incidence of the COVID-19 hotspot in Iran -Implications for Travellers

An interactive web-based dashboard to track COVID-19 in real time

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Airborne or droplet precautions for health workers treating COVID-19?

CDC updates guidance on PPE for health care personnel; COVID-19 declared a pandemic

Facemask shortage and the novel coronavirus disease (COVID-19) outbreak: Reflections on public health measures

Shortage of personal protective equipment endangering health workers worldwide

Consistent detection of 2019 novel coronavirus in saliva

Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis

Surveillance of Acute Respiratory Infections Using Community-Submitted Symptoms and Specimens for Molecular Diagnostic Testing

Walk-Through Screening Center for COVID-19: An Accessible and Efficient Screening System in a Pandemic Situation

Evaluation of saline, phosphate buffered saline and minimum essential medium as potential alternatives to viral transport media for SARS-CoV-2 testing

Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease

World Health Organization (WHO)

Broad-spectrum microbicidal activity, toxicologic assessment, and materials compatibility of a new generation of accelerated hydrogen peroxide-based environmental surface disinfectant

Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents

Stability and inactivation of SARS coronavirus

Inactivation of SARS coronavirus by means of povidoneiodine, physical conditions and chemical reagents

Efficacy of various disinfectants against SARS coronavirus

Virucidal Activity of World Health OrganizationRecommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses

Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)

Why is SARS-CoV-2 testing not possible in every medical laboratory?

Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea

Stability of SARS-CoV-2 in different environmental conditions

Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia

Virus inactivation by nucleic acid extraction reagents

The effect of a non-denaturing detergent and a guanidinium-based inactivation agent on the viability of Ebola virus in mock clinical serum samples

Potential false-negative nucleic acid testing results for Severe Acute Respiratory Syndrome Coronavirus 2 from thermal inactivation of samples with low viral loads

Laboratory containment of SARS virus

Prudently conduct the engineering and synthesis of the SARS-CoV-2 virus

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2

The authors like to acknowledge and thank their individual institutions.